Pyxis Oncology, Inc. (NASDAQ:PYXS – Free Report) – HC Wainwright lifted their Q3 2026 earnings per share (EPS) estimates for Pyxis Oncology in a research report issued on Tuesday, August 18th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.26) for the quarter, up from their prior forecast of ($0.27). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.08) EPS, Q1 2027 earnings at ($0.18) EPS, Q2 2027 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.18) EPS, Q4 2027 earnings at ($0.19) EPS, FY2027 earnings at ($0.73) EPS, FY2028 earnings at ($0.35) EPS and FY2029 earnings at $0.23 EPS.
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05).
Read Our Latest Stock Analysis on Pyxis Oncology
Pyxis Oncology Trading Up 12.7%
Shares of NASDAQ PYXS opened at $3.37 on Thursday. The firm has a market cap of $213.49 million, a P/E ratio of -2.39 and a beta of 1.31. The business’s 50 day moving average is $2.64 and its 200-day moving average is $2.01. Pyxis Oncology has a 1-year low of $1.03 and a 1-year high of $5.55.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its stake in shares of Pyxis Oncology by 22.0% in the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock valued at $1,297,000 after acquiring an additional 160,300 shares during the last quarter. J. Derek Lewis & Associates Inc. acquired a new stake in Pyxis Oncology during the 4th quarter worth approximately $61,000. XTX Topco Ltd boosted its position in Pyxis Oncology by 1,533.0% during the 4th quarter. XTX Topco Ltd now owns 289,033 shares of the company’s stock worth $332,000 after buying an additional 271,334 shares during the period. Toronto Dominion Bank bought a new stake in Pyxis Oncology during the 4th quarter worth approximately $86,000. Finally, Quadrature Capital Ltd bought a new stake in Pyxis Oncology during the 4th quarter worth approximately $116,000. 39.07% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about Pyxis Oncology
Here are the key news stories impacting Pyxis Oncology this week:
- Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $1.08 from a loss of $1.10 and its FY2027 forecast to a loss of $0.73 from a loss of $0.88. The firm also improved estimates for several 2027 quarters, signaling expectations for reduced operating losses. MarketBeat Pyxis Oncology analyst estimates
- Positive Sentiment: Longer-term projections were upgraded, including FY2028 EPS to a loss of $0.35 from a loss of $0.44 and FY2029 EPS to positive earnings of $0.23 from $0.20. These changes reinforce the analyst’s view that Pyxis could reach profitability in the forecast period. HC Wainwright reaffirms Buy rating for Pyxis Oncology
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $7.00 price objective. The continued bullish stance may support investor sentiment toward the biotechnology company. Benzinga analyst rating report
- Neutral Sentiment: Despite the improved forecasts, Pyxis Oncology remains unprofitable, with consensus estimates calling for a $1.22 per-share loss for the current fiscal year. The company’s latest reported quarter also missed expectations, highlighting ongoing execution and financing risks.
- Negative Sentiment: HC Wainwright made a minor reduction to its FY2030 EPS estimate, lowering projected earnings to $0.76 from $0.77. The change is small but contrasts with the broader upgrades.
About Pyxis Oncology
Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.
Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.
Featured Stories
- Five stocks we like better than Pyxis Oncology
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
